A Phase 1 interventional study of Transcutaneous electrical acustimulation in automatic synchronization with breathing in Functional Dyspepsia, sponsored by MetroHealth Medical Center. Active, not recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by MetroHealth Medical Center · Phase 1, Interventional, and Device feasibility
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 77 studies in Dyspepsia with a site in United States — 14 open to participants now, 18 under way, 1 of them phase 3. Dyspepsia · United States.
Among the 77 studies in Dyspepsia with a site in United States, this one is the 51st largest by planned enrollment of the 67 interventional ones that give a count, is one of 4 that started in 2025, is one of 6 in phase 1, reaches primary completion later than 15 of the 17 other live ones, and was the 73rd registered.
373 studies on the registry are indexed under Dyspepsia; 67 are open to participants now.
Browse Dyspepsia studies →14 of the 77 studies in Dyspepsia with a site in United States are open now. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18+
Ohio State University · Sites in United States
Ages 18+
Spaulding Rehabilitation Hospital · Sites in United States
Ages 18–65
Hospital Universitari Vall d'Hebron Research Institute · Sites in United States, Canada, France and 4 more countries
Ages 18–80 · Healthy volunteers
Mayo Clinic · Sites in United States
Ages 18–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 46 Dyspepsia studies recruiting now, 16 (35%) set no upper age limit and 23 (50%) stop at 75 or younger; 2 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
77 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 14 · Phase 3 13 · Phase 4 2
First in 1999; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 88 across 303 interventional studies indexed under Dyspepsia.
Median enrollment 50 across the 67 interventional studies, 41 across the 10 observational. Of the 52 that completed or were terminated, 14 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 77 have an industry lead sponsor. The 10 most frequent:
MetroHealth Medical Center is the lead sponsor of 104 studies on the registry; 20 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 7 (58%) have results posted.
MetroHealth Medical Center has 1 study filed under Dyspepsia — fewer than ten, so there is no comparison to draw.
7 of the studies in Dyspepsia with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01696734Phase 3M.D. Anderson Cancer CenterDomperidone in Treating Patients With Gastrointestinal Disorders | 2027-10-31 |
| NCT05836597Mayo ClinicFunctional Dyspepsia Treatment Using Virtual Reality | 2026-12 |
| NCT06941545Mayo ClinicHigh Resolution Gastric Mapping and Gastroduodenal Manometry | 2026-12-31 |
| NCT05653310Xiao Jing (Iris) WangTradipitant for Functional Dyspepsia | 2027-03 |
| NCT06369753Hospital Universitari Vall d'Hebron Research InstituteVisible Abdominal Distension | 2027-04 |
Add all 7 to your calendar (.ics) → With an account.
Among the 77 studies in Dyspepsia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this study is to assess how effective the AutoSTEA device is in treating functional dyspepsia (upper abdominal discomfort) in adults. It will also assess the safety and usability of the device. The main questions it aims to answer are:
Participants will:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The treatment this arm will be administered is the AutoSTEA treatment, which consists of a band-like device that wraps around the rib cage. This device is connected to a microstimulator which is then connected to TENS pads. The band allows for the electrical impulses given to be synchronized with one's breathing.
Device: Transcutaneous electrical acustimulation in automatic synchronization with breathing
This intervention will be carried out via the AutoSTEA device.
Determine the device safety when self-administered at home by patients
Assess any adverse effects the device may have when used by patients in their home. This will be done using the device safety questionnaire. The safety questionnaire is to filled out weekly, with any adverse event that is experienced being reported. These adverse events (if applicable) will be rated in severity on a 0-5 scale, with 0 being the least severe and 5 being the most severe.
Time frame: From enrollment to the end of treatment in two weeks
Evaluate device usability
Assess how easy the device is for patients to use in their home. This will be done using the usability questionnaire. This questionnaire will be filled out daily and the user will rate on a 0-5 scale (with 0 being the worst and 5 being the best) how easy and comfortable the device was for them.
Time frame: From enrollment to the end of treatment in two weeks
Assess symptom responses to treatment
Assess how well a patient's dyspepsia symptoms respond to the treatment. This will be done via two questionnaires. One will be filled out weekly, where patients describe how much their dyspepsia symptoms have affected their daily lives. The scale for this will be 0-4, with 0 being no effect on their daily life and 5 being extreme effect on their daily lives. The second questionnaire will be filled out daily, and it describes the physical dyspepsia symptoms experienced by the patient in the last 24 hours. It is done on a scale from 0-10, with 0 meaning they have not experienced a symptom at all, and 10 being they have severely experienced a symptom.
Time frame: From enrollment to the end of treatment in two weeks
Assess a diverse participant pool, especially overweight/obese female patients
Assess the response that patients have with a focus on those who are overweight/obese and female. This will be analyzed via the two dyspepsia symptom questionnaires that are mentioned in outcome 3.
Time frame: From enrollment to the end of treatment in two weeks
Assess patient's compliance to AutoSTEA treatment
Assess if patients followed through with the required usage of the device and treatment. This will be done via their own self-reporting to study staff of if they missed any treatment days.
Time frame: From enrollment to the end of treatment in two weeks
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — This data is preliminary data which we will use for IP protection and pattern application. We will keep the data confidential prior to future publication.
Started Feb 2025 (actual). Primary completion is estimated for Jan 2030, 59 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 3, 2026: primary completion Apr 2026 → Jan 2030 and completion Feb 2027 → Jul 2030.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.